Lundbeck increased revenue by 5% driven by US sales growth

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016

Valby, Denmark, 2016-08-24 07:51 CEST (GLOBE NEWSWIRE) -- HIGHLIGHTS

  • Revenue reached DKK 7,521 million in the first half of 2016 representing an increase of 5% in both reported and local currencies compared to the same period last year
    • Total revenue has delivered a better performance than expected driven by Xenazine® and key products
    • US revenue increased 33% (31% in local currency) to DKK 3,840 million
    • Revenue in International Markets declined 5% (unchanged in local currencies) to DKK 2,033 million
    • Europe declined 26% (25% in local currencies) to DKK 1,453 million
  • Revenue from key products grew 99% (99% in local currencies) to DKK 2,902 million in the period representing 39% of total revenue
    • Abilify Maintena® sees strong growth reaching DKK 534 million. The growth of 93% (94% in local currencies) was driven by all regions, but particularly by Europe
    • Brintellix®/Trintellix sales grew 103% and reached DKK 482 million, with non-US markets contributing DKK 220 million or 46% of total Brintellix sales
    • Northera® sales reached DKK 449 million, up 203% (201% in local currency)
    • Onfi® continues its solid performance growing 42% (40% in local currency) to DKK 1,128 million
    • Rexulti® was launched in the US in August 2015 and revenue reached DKK 309 million  
  • In the first half of 2016, the EBIT-margin reached 12.7% compared to a negative margin of 67.6% in the same period in 2015. In 2015, EBIT included an impairment loss of DKK 4.8 billion
  • Following the solid performance, Lundbeck now expects revenue of around DKK 14.6-15.0 billion and EBIT is expected to reach DKK 1.5-1.7 billion for 2016 compared to previously DKK 14.2-14.6 billion and DKK 1.3-1.5 billion, respectively

In connection with the financial report, Lundbeck’s President and CEO, Kåre Schultz said:

“I am very pleased with the continued strong sales growth of our key products and the increase of our financial guidance. We are on track to improve our profitability and I am excited about our R&D pipeline.”

DKK million H1 2016  H1 2015 Growth
Reported Revenue 7,521 7,192 5%
Reported EBIT 952 (4,865) -
Reported EPS 2.12 (20.26) -
Reported EBIT margin 12.7% (67.6%) -
       
Core Revenue* 7,521 7,192 5%
Core EBIT* 1,475 351 320%
Core EBIT margin* 19.6% 4.9% 300%

*For definition of the measures “Core Revenue” and “Core EBIT”, see note 3 Core reporting

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 501

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 564

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 707

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 112

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 496

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading